Sugi Predict

Sugi Predict / Compounds / SCHEMBL17839738

SCHEMBL17839738

SCHEMBL17839738

O=C(O)NCCCCCCCCNC(=O)CCl

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.81
▸ SMN1; SMN2 Q16637 1/20 0.81
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CASP2 P42575 1/20 0.43
▸ ALDH1A2 O94788 1/20 0.43
▸ ALDH2 P05091 1/20 0.43
▸ ALDH1A3 P47895 1/20 0.43
▸ FAAH O00519 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ PRMT1 Q99873 1/20 0.41
▸ NAAA Q02083 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ EPHX1 P07099 2/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17839791 1.00 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL19611932 0.98 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL11126451 0.90 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL17839852 0.87 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MEN1KMT2AFAAH
SCHEMBL11127833 0.87 ALDH1A1 (0.94) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL5569558 0.84 KDM4E (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL15871737 0.84 KDM4E (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL20836564 0.84 KDM4E (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL2029681 0.84 KDM4E (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2
SCHEMBL453216 0.84 KDM4E (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ACASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
EP-3256470-B1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA FARBER CANCER INST INC (US) 2023-07-26 — — EP disclosed
US-11583586-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-02-21 — — US disclosed
EP-4119552-A1 REGULATING CHIMERIC ANTIGEN RECEPTORS Dana-Farber Cancer Institute, Inc. (US) 2023-01-18 — — EP disclosed
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 — — US disclosed
US-11311609-B2 Regulating chimeric antigen receptors DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-26 — — US disclosed
US-20210301286-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-30 — — US disclosed
US-11059801-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-07-13 — — US disclosed
US-11046954-B2 Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-06-29 — — US disclosed
US-20210015929-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-01-21 — — US disclosed
US-9694084-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-04 — — US disclosed
WO-2017024318-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-09 — — WO disclosed
WO-2017024317-A2 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-09 — — WO disclosed
WO-2017024319-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-09 — — WO disclosed
WO-2017007612-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-01-12 — — WO disclosed
US-20160243247-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. 2016-08-25 — — US disclosed
US-20160235731-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. 2016-08-18 — — US disclosed
US-20160235730-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. 2016-08-18 — — US disclosed
WO-2016105518-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-30 — — WO disclosed
US-20160176916-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160243247-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-20210301286-A1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES NFATC1, GZMB, ICOS ALDH1A1 4524/4885SMN1; SMN2 2584/4885MEN1 2869/4885
US-11583586-B2 Methods to induce targeted protein degradation through bifunctional molecules CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-11059801-B2 Methods to induce targeted protein degradation through bifunctional molecules CRBN, XIAP, MDM2 ALDH1A1 3984/4885SMN1; SMN2 2672/4885MEN1 2152/4885
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 ALDH1A1 4238/4885SMN1; SMN2 4198/4885MEN1 2833/4885
US-20160235731-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-11046954-B2 Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses NFATC1, GZMB, ICOS ALDH1A1 4524/4885SMN1; SMN2 2584/4885MEN1 2869/4885
US-20210015929-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-20160235730-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-11311609-B2 Regulating chimeric antigen receptors NFATC1, TNFRSF9, IL2RA ALDH1A1 4691/4885SMN1; SMN2 2808/4885MEN1 2368/4885
US-20160176916-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP ALDH1A1 3779/4885SMN1; SMN2 2174/4885MEN1 2073/4885
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 ALDH1A1 4528/4885SMN1; SMN2 4262/4885MEN1 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.